U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2O2
Molecular Weight 194.2304
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLRIAMFETOL

SMILES

N[C@@H](COC(N)=O)CC1=CC=CC=C1

InChI

InChIKey=UCTRAOBQFUDCSR-SECBINFHSA-N
InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1

HIDE SMILES / InChI

Description

ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wakefulness in adult patients with hypersomnia associated with narcolepsy or obstructive sleep apnoea.The US FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.4 µM [IC50]
2.9 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
2015 Sep
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
2016 Jul 1
New developments in the management of narcolepsy.
2017

Sample Use Guides

In Vivo Use Guide
The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.
Route of Administration: Oral
In Vitro Use Guide
Solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity (Ki=14.2 uM and 3.7 uM, respectively), and inhibits the reuptake of dopamine and norepinephrine with low potency (IC50 =2.9 uM and 4.4 uM, respectively). Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 uM) and does not inhibit serotonin reuptake (IC50 > 100 uM).
Name Type Language
SOLRIAMFETOL
USAN   INN  
Official Name English
(2R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
Systematic Name English
YKP-10A
Code English
R-228060
Code English
SOLRIAMFETOL [WHO-DD]
Common Name English
SUNOSI
Brand Name English
BENZENEPROPANOL, .BETA.-AMINO-, CARBAMATE (ESTER), (R)-
Systematic Name English
BENZENEPROPANOL, .BETA.-AMINO-, 1-CARBAMATE, (.BETA.R)-
Systematic Name English
JZP-110
Code English
SOLRIAMFETOL [INN]
Common Name English
ADX-N-05
Code English
SKL-N-05
Code English
SOLRIAMFETOL [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78272
Created by admin on Mon Oct 21 22:40:18 UTC 2019 , Edited by admin on Mon Oct 21 22:40:18 UTC 2019
Code System Code Type Description
INN
10117
Created by admin on Mon Oct 21 22:40:18 UTC 2019 , Edited by admin on Mon Oct 21 22:40:18 UTC 2019
PRIMARY
CAS
178429-62-4
Created by admin on Mon Oct 21 22:40:18 UTC 2019 , Edited by admin on Mon Oct 21 22:40:18 UTC 2019
PRIMARY
PUBCHEM
10130337
Created by admin on Mon Oct 21 22:40:18 UTC 2019 , Edited by admin on Mon Oct 21 22:40:18 UTC 2019
PRIMARY
NCI_THESAURUS
C152389
Created by admin on Mon Oct 21 22:40:18 UTC 2019 , Edited by admin on Mon Oct 21 22:40:18 UTC 2019
PRIMARY